Buy Epivir Hbv

Epivir Hbv

What is Epivir HBV?

Epivir HBV is a prescription-only (POM) antiviral medication marketed in the United Kingdom. The product contains lamivudine 100 mg as its sole active ingredient and is supplied as an oral pill. Lamivudine belongs to the nucleoside reverse-transcriptase inhibitor (NRTI) class and is used primarily to treat chronic infection with hepatitis B virus (HBV). The medication is authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) and is manufactured by GlaxoSmithKline (original brand owner).

How Lamivudine Works in the Body

Lamivudine is a synthetic analogue of the nucleoside cytidine. After oral absorption, it is phosphorylated inside cells to the active triphosphate form, lamivudine-triphosphate. This active metabolite competes with the natural substrate deoxycytidine-triphosphate for incorporation into viral DNA by the reverse-transcriptase enzyme of HBV (and HIV).

• Chain termination: Once incorporated, lamivudine-triphosphate prevents the addition of further nucleotides, halting viral DNA synthesis.
• Reduced viral replication: By suppressing HBV DNA production, the drug lowers the amount of virus circulating in the bloodstream and reduces liver inflammation.
• Onset and duration: Antiviral activity begins within a few days of the first dose; steady-state plasma concentrations are usually achieved after 5-7 days of once-daily dosing.
• Metabolism and excretion: Lamivudine is minimally metabolised and is eliminated primarily unchanged by the kidneys (≈70 % excreted in urine).

Approved Medical Uses

Epivir HBV is licensed in the UK for the following indications:

• Chronic hepatitis B infection in adults with compensated liver disease, as defined by normal or mildly impaired liver function (Child-Pugh A).
• HBV/HIV co-infection where lamivudine is required as part of an antiretroviral regimen (always in combination with other agents, not as monotherapy for HIV).

The medication is intended for patients who have measurable HBV DNA levels and who require long-term viral suppression to prevent progression to cirrhosis, liver failure, or hepatocellular carcinoma.

Evidence-Based Off-Label Uses

Lamivudine is included in many fixed-dose combinations for HIV treatment (e.g., 3TC/ABC/DTG). While Epivir HBV is labelled for HBV, clinicians sometimes prescribe lamivudine-containing regimens for HIV-positive patients who need an additional NRTI. This use is off-label for the standalone 100 mg tablet and must be managed by a specialist HIV physician.

• Off-label indication: HIV-1 infection as part of a combination antiretroviral therapy.
• Evidence level: Supported by numerous randomised clinical trials of lamivudine-based HAART regimens, but monotherapy is not recommended due to rapid resistance development.
• Regulatory status: Not approved by the MHRA for HIV monotherapy; any off-label use requires explicit medical supervision.

Disclaimer: Off-label use of Epivir HBV should only be undertaken after a thorough risk-benefit assessment by a qualified healthcare professional.

Patient Suitability and Contraindications

Who Should Use Epivir HBV?

• Adults with chronic HBV infection who meet the indication criteria (compensated liver disease).
• Patients with HBV/HIV co-infection who require lamivudine as part of a multi-drug regimen.

Absolute Contraindications

• Known hypersensitivity to lamivudine or any excipients in the tablet.
• Severe hepatic impairment (Child-Pugh C) where the risk of drug-induced liver decompensation outweighs benefit.

Relative Contraindications & Precautions

• Renal impairment: Dose adjustment is required when creatinine clearance (CrCl) < 50 mL/min.
• Pregnancy & lactation: Lamivudine is classified as Category B in the UK (no proven risk in animal studies, limited human data). Use only if the expected benefit justifies potential risk.
• Elderly patients: May have reduced renal function; monitor renal parameters before and during therapy.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Headache - usually mild and transient.
• Nausea or vomiting - often resolves after the first few days.
• Fatigue - reported in up to 10 % of patients.
• Diarrhoea - occasional, generally self-limiting.

Serious Adverse Events

• Lactic acidosis and hepatic steatosis - rare but potentially fatal; watch for unexplained abdominal pain, rapid breathing, or marked weakness.
• Severe hepatitis flare on abrupt discontinuation, especially in patients with underlying liver disease.
• Pancreatitis - increased risk when lamivudine is combined with didanosine.

Drug Interactions

• Didanosine - co-administration markedly raises the risk of pancreatitis; avoid unless strictly required and closely monitored.
• Nephrotoxic agents (e.g., aminoglycosides, vancomycin) - may exacerbate renal dysfunction; adjust lamivudine dose accordingly.
• Other NRTIs - additive mitochondrial toxicity; monitor liver enzymes and lactate levels.
• CYP enzymes: Lamivudine is not a significant substrate, inhibitor, or inducer of cytochrome P450; most drug-drug interactions are pharmacodynamic rather than metabolic.

Food and Lifestyle Interactions

• Lamivudine can be taken with or without food; however, taking it with a meal may improve gastrointestinal tolerance.
• Alcohol should be limited, as both alcohol and lamivudine can stress the liver.
• No known effects on driving or the use of machinery, but severe adverse reactions (e.g., lactic acidosis) could impair performance.

How to Take Epivir HBV

• Standard dose: One tablet (100 mg) once daily, preferably at the same time each day.
• Renal adjustment: For patients with CrCl < 50 mL/min, the recommended dose is 50 mg once daily (a split-tablet regimen may be used under medical supervision).
• Administration: Swallow the tablet whole with a glass of water. Crushing or chewing is not advised.
• Missed dose: If a dose is missed and it is less than 12 hours until the next scheduled dose, skip the missed tablet and continue with the regular schedule. Do not double-dose.
• Overdose: Symptoms may include nausea, vomiting, dizziness, and severe lactic acidosis. Seek emergency assistance; treatment is mainly supportive, with haemodialysis considered in severe renal failure.
• Discontinuation: Abrupt cessation can trigger a hepatitis flare. Tapering is not required pharmacologically, but liver function should be closely monitored when stopping therapy.

Monitoring and Follow-Up

• Baseline assessments: Liver function tests (ALT, AST, bilirubin), HBV DNA quantification, renal function (serum creatinine, eGFR).
• Ongoing monitoring:
• Liver enzymes every 3-6 months while on therapy.
• HBV DNA levels to confirm viral suppression (usually after 3 months, then periodically).
• Serum lactate if patient develops unexplained fatigue, nausea, or metabolic acidosis signs.
• When to seek medical help: New or worsening abdominal pain, yellowing of the skin or eyes, shortness of breath, or sudden weakness.

Storage and Handling

• Store tablets at ≤ 30 °C, away from moisture and direct sunlight.
• Keep the container tightly closed and out of reach of children and pets.
• Do not use the medication after the expiry date printed on the pack.
• If a tablet becomes damaged or discoloured, discard it safely and obtain a new supply.

Medication-Specific Glossary

Reverse-Transcriptase Inhibitor

A drug that blocks the activity of reverse-transcriptase, an enzyme viruses use to convert their RNA genome into DNA.

HBV DNA

The viral genetic material circulating in the bloodstream; measurement of HBV DNA levels indicates the amount of active viral replication.

Lactic Acidosis

A serious metabolic disturbance characterised by elevated blood lactate and reduced pH, potentially life-threatening if not recognised promptly.

Compensated Liver Disease

A stage of chronic liver disease where the liver can still perform its essential functions despite ongoing injury, reflected by near-normal laboratory values.

Medical Disclaimer

This article provides educational information about Epivir HBV and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.